[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100454417":3},{"organization":4,"armGroups":7,"interventions":45,"overallOfficials":56,"centralContacts":60,"locations":66,"responsibleParty":438,"collaborators":51,"id":440,"slug":441,"hasResults":442,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":51,"eligibilityCriteria":446,"healthyVolunteers":442,"sex":447,"minAge":448,"maxAge":51,"enrollmentInfo":449,"targetDuration":51,"studyType":452,"phases":453,"briefSummary":456,"conditions":457,"keywords":459,"overallStatus":69,"whyStopped":51,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":483},{"fullName":5,"class":6},"4D Molecular Therapeutics","INDUSTRY",[8,14,17,20,26,29,32,35,39,42],{"label":9,"type":10,"description":11,"interventionNames":12},"4D-150 Dose Escalation up to 4 dose levels","EXPERIMENTAL","4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.",[13],"Biological: 4D-150 IVT",{"label":15,"type":10,"description":11,"interventionNames":16},"4D-150 Dose Expansion Dose 1",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"4D-150 Dose Expansion Dose 2",[13],{"label":21,"type":22,"description":23,"interventionNames":24},"4D-150 Dose Expansion Control","ACTIVE_COMPARATOR","Aflibercept at a fixed regimen will be administered.",[25],"Biological: Aflibercept IVT",{"label":27,"type":10,"description":11,"interventionNames":28},"4D-150 Steroid Optimization",[13],{"label":30,"type":10,"description":11,"interventionNames":31},"4D-150 Population Extension Dose 1",[13],{"label":33,"type":10,"description":11,"interventionNames":34},"4D-150 Population Extension Dose 2",[13],{"label":36,"type":10,"description":37,"interventionNames":38},"4D-150 Population Extension Dose 3","4D-150 will be administered at the assigned dose",[13],{"label":40,"type":10,"description":11,"interventionNames":41},"4D-150 Contralateral Eye Dose",[13],{"label":43,"type":10,"description":11,"interventionNames":44},"4D-150 Vector Shedding Dose",[13],[46,52],{"type":47,"name":48,"description":49,"armGroupLabels":50,"otherNames":51},"BIOLOGICAL","4D-150 IVT","4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept",[40,9,15,18,30,33,36,27,43],null,{"type":47,"name":53,"description":54,"armGroupLabels":55,"otherNames":51},"Aflibercept IVT","Commercially available Active Comparator Other Name: Eylea",[21],[57],{"name":58,"affiliation":5,"role":59},"Demi Dang, MD","STUDY_DIRECTOR",[61],{"name":62,"role":63,"phone":64,"phoneExt":51,"email":65},"4DMT Patient Advocacy","CONTACT","(888) 748-8881","clinicaltrials@4DMT.com",[67,88,104,119,135,146,156,171,186,201,216,232,248,264,280,296,307,323,339,355,371,387,402,411,421],{"facility":68,"status":69,"city":70,"state":71,"zip":72,"country":73,"countryCode":74,"cosmosGeoPoint":75,"geoPoint":80,"contacts":81},"Barnet Delaney Perkins Eye Center","RECRUITING","Phoenix","Arizona","85016","United States","US",{"type":76,"coordinates":77},"Point",[78,79],-112.07404,33.44838,{"lat":79,"lon":78},[82,85],{"name":83,"role":63,"phone":51,"phoneExt":51,"email":84},"Dallin Stuart","Dallin.stuart@researchavp.com",{"name":86,"role":87,"phone":51,"phoneExt":51,"email":51},"Suhail Alam, M.D.","PRINCIPAL_INVESTIGATOR",{"facility":89,"status":69,"city":90,"state":91,"zip":92,"country":73,"countryCode":74,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"California Retina Consultants","Oxnard","California","93036",{"type":76,"coordinates":94},[95,96],-119.17705,34.1975,{"lat":96,"lon":95},[99,102],{"name":100,"role":63,"phone":51,"phoneExt":51,"email":101},"Annette Beltran-Almaza","annett.almazan@californiaretina.com",{"name":103,"role":87,"phone":51,"phoneExt":51,"email":51},"Dante Pieramici, M.D.",{"facility":105,"status":69,"city":106,"state":91,"zip":107,"country":73,"countryCode":74,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"Retinal Consultants Medical Group","Sacramento","95841",{"type":76,"coordinates":109},[110,111],-121.4944,38.58157,{"lat":111,"lon":110},[114,117],{"name":115,"role":63,"phone":51,"phoneExt":51,"email":116},"Rashin Sedighi","sedighir@retinalmd.com",{"name":118,"role":87,"phone":51,"phoneExt":51,"email":51},"Joel Pearlman, M.D., Ph.D.",{"facility":120,"status":69,"city":121,"state":122,"zip":123,"country":73,"countryCode":74,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"Colorado Retina Associates","Lakewood","Colorado","80288",{"type":76,"coordinates":125},[126,127],-105.08137,39.70471,{"lat":127,"lon":126},[130,133],{"name":131,"role":63,"phone":51,"phoneExt":51,"email":132},"Lindsay Harrigan","lharrigan@retinacolorado.com",{"name":134,"role":87,"phone":51,"phoneExt":51,"email":51},"Murtaza Adam, MD",{"facility":136,"status":137,"city":138,"state":139,"zip":140,"country":73,"countryCode":74,"cosmosGeoPoint":141,"geoPoint":145,"contacts":51},"Rand Eye Institute","SUSPENDED","Deerfield Beach","Florida","33064",{"type":76,"coordinates":142},[143,144],-80.09977,26.31841,{"lat":144,"lon":143},{"facility":147,"status":148,"city":149,"state":139,"zip":150,"country":73,"countryCode":74,"cosmosGeoPoint":151,"geoPoint":155,"contacts":51},"Retina Vitreous Consultants, LLP DBA Retina Group of Florida","ACTIVE_NOT_RECRUITING","Fort Lauderdale","33308",{"type":76,"coordinates":152},[153,154],-80.14338,26.12231,{"lat":154,"lon":153},{"facility":157,"status":69,"city":158,"state":139,"zip":159,"country":73,"countryCode":74,"cosmosGeoPoint":160,"geoPoint":164,"contacts":165},"Vitreo Retinal Associates","Gainesville","32607",{"type":76,"coordinates":161},[162,163],-82.32483,29.65163,{"lat":163,"lon":162},[166,169],{"name":167,"role":63,"phone":51,"phoneExt":51,"email":168},"Jing Zhang","jingzhang@vra-pa.com",{"name":170,"role":87,"phone":51,"phoneExt":51,"email":51},"Christine Kay, M.D.",{"facility":172,"status":69,"city":173,"state":139,"zip":174,"country":73,"countryCode":74,"cosmosGeoPoint":175,"geoPoint":179,"contacts":180},"Florida Eye Associates","Melbourne","32901",{"type":76,"coordinates":176},[177,178],-80.60811,28.08363,{"lat":178,"lon":177},[181,184],{"name":182,"role":63,"phone":51,"phoneExt":51,"email":183},"Melissa Dougherty","MDougherty@floridaeyeassociates.com",{"name":185,"role":87,"phone":51,"phoneExt":51,"email":51},"Vrinda Hershberger, M.D., Ph.D.",{"facility":187,"status":69,"city":188,"state":139,"zip":189,"country":73,"countryCode":74,"cosmosGeoPoint":190,"geoPoint":194,"contacts":195},"Retinal Specialty Institute","Pensacola","32503",{"type":76,"coordinates":191},[192,193],-87.21691,30.42131,{"lat":193,"lon":192},[196,199],{"name":197,"role":63,"phone":51,"phoneExt":51,"email":198},"Vera Watkins, R.N.","vwatkins@retinaspecialty.com",{"name":200,"role":87,"phone":51,"phoneExt":51,"email":51},"Sunil Gupta, M.D.",{"facility":202,"status":69,"city":203,"state":139,"zip":204,"country":73,"countryCode":74,"cosmosGeoPoint":205,"geoPoint":209,"contacts":210},"Retina Vitreous Associates of Florida","Tampa","33607",{"type":76,"coordinates":206},[207,208],-82.45843,27.94752,{"lat":208,"lon":207},[211,214],{"name":212,"role":63,"phone":51,"phoneExt":51,"email":213},"Kimberly Velez","kvelez@rvaf.com",{"name":215,"role":87,"phone":51,"phoneExt":51,"email":51},"David Eichenbaum, M.D.",{"facility":217,"status":69,"city":218,"state":219,"zip":220,"country":73,"countryCode":74,"cosmosGeoPoint":221,"geoPoint":225,"contacts":226},"University Retina and Macula Associates","Oak Forest","Illinois","60452",{"type":76,"coordinates":222},[223,224],-87.74394,41.60281,{"lat":224,"lon":223},[227,230],{"name":228,"role":63,"phone":51,"phoneExt":51,"email":229},"Cindy Vallejo","cvallejo@uretina.com",{"name":231,"role":87,"phone":51,"phoneExt":51,"email":51},"Veeral Sheth, M.D.",{"facility":233,"status":69,"city":234,"state":235,"zip":236,"country":73,"countryCode":74,"cosmosGeoPoint":237,"geoPoint":241,"contacts":242},"Retina Partners Midwest","Carmel","Indiana","46290",{"type":76,"coordinates":238},[239,240],-86.11804,39.97837,{"lat":240,"lon":239},[243,246],{"name":244,"role":63,"phone":51,"phoneExt":51,"email":245},"Lorraine White","startup@midwesteye.com",{"name":247,"role":87,"phone":51,"phoneExt":51,"email":51},"Raj Maturi, MD",{"facility":249,"status":69,"city":250,"state":251,"zip":252,"country":73,"countryCode":74,"cosmosGeoPoint":253,"geoPoint":257,"contacts":258},"Cumberland Valley Retina Consultants","Hagerstown","Maryland","21740",{"type":76,"coordinates":254},[255,256],-77.71999,39.64176,{"lat":256,"lon":255},[259,262],{"name":260,"role":63,"phone":51,"phoneExt":51,"email":261},"Emma Melvin","emelvin@retinacare.net",{"name":263,"role":87,"phone":51,"phoneExt":51,"email":51},"Allen Hu, M.D.",{"facility":265,"status":69,"city":266,"state":267,"zip":268,"country":73,"countryCode":74,"cosmosGeoPoint":269,"geoPoint":273,"contacts":274},"Ophthalmic Consultants of Boston & Boston Eye Surgery and Laser Center","Boston","Massachusetts","02114",{"type":76,"coordinates":270},[271,272],-71.05977,42.35843,{"lat":272,"lon":271},[275,278],{"name":276,"role":63,"phone":51,"phoneExt":51,"email":277},"Quinn Hogan","qhogan@eyeboston.com",{"name":279,"role":87,"phone":51,"phoneExt":51,"email":51},"Jeffrey Heier, MD",{"facility":281,"status":69,"city":282,"state":283,"zip":284,"country":73,"countryCode":74,"cosmosGeoPoint":285,"geoPoint":289,"contacts":290},"Sierra Eye Associates","Reno","Nevada","89502",{"type":76,"coordinates":286},[287,288],-119.8138,39.52963,{"lat":288,"lon":287},[291,294],{"name":292,"role":63,"phone":51,"phoneExt":51,"email":293},"Huma Khan","humak@sierraeyeassociates.com",{"name":295,"role":87,"phone":51,"phoneExt":51,"email":51},"Arshad Khanani, M.D., M.A.",{"facility":297,"status":298,"city":299,"state":300,"zip":301,"country":73,"countryCode":74,"cosmosGeoPoint":302,"geoPoint":306,"contacts":51},"Western Carolina Retinal Associates","WITHDRAWN","Asheville","North Carolina","28803",{"type":76,"coordinates":303},[304,305],-82.55402,35.60095,{"lat":305,"lon":304},{"facility":308,"status":69,"city":309,"state":310,"zip":311,"country":73,"countryCode":74,"cosmosGeoPoint":312,"geoPoint":316,"contacts":317},"Verum Research, LLC","Eugene","Oregon","97401",{"type":76,"coordinates":313},[314,315],-123.08675,44.05207,{"lat":315,"lon":314},[318,321],{"name":319,"role":63,"phone":51,"phoneExt":51,"email":320},"Lillian Carroll","lcarroll@verumresearch.com",{"name":322,"role":87,"phone":51,"phoneExt":51,"email":51},"Albert Edwards, MD",{"facility":324,"status":69,"city":325,"state":326,"zip":327,"country":73,"countryCode":74,"cosmosGeoPoint":328,"geoPoint":332,"contacts":333},"Mid Atlantic Retina","Bethlehem","Pennsylvania","18017",{"type":76,"coordinates":329},[330,331],-75.37046,40.62593,{"lat":331,"lon":330},[334,337],{"name":335,"role":63,"phone":51,"phoneExt":51,"email":336},"Leah Kritzwiser","lkritzwiser@midatlanticretina.com",{"name":338,"role":87,"phone":51,"phoneExt":51,"email":51},"Ajay Kuriyan, MD",{"facility":340,"status":69,"city":341,"state":342,"zip":343,"country":73,"countryCode":74,"cosmosGeoPoint":344,"geoPoint":348,"contacts":349},"Palmetto Retina Center, LLC","West Columbia","South Carolina","29169",{"type":76,"coordinates":345},[346,347],-81.07398,33.99349,{"lat":347,"lon":346},[350,353],{"name":351,"role":63,"phone":51,"phoneExt":51,"email":352},"Pamala Tims","ptims@palmettoretina.com",{"name":354,"role":87,"phone":51,"phoneExt":51,"email":51},"John Wells, MD",{"facility":356,"status":69,"city":357,"state":358,"zip":359,"country":73,"countryCode":74,"cosmosGeoPoint":360,"geoPoint":364,"contacts":365},"Tennessee Retina","Nashville","Tennessee","37203",{"type":76,"coordinates":361},[362,363],-86.78444,36.16589,{"lat":363,"lon":362},[366,369],{"name":367,"role":63,"phone":51,"phoneExt":51,"email":368},"Lisa Walden","LWalden@tnretina.com",{"name":370,"role":87,"phone":51,"phoneExt":51,"email":51},"Carl Awh, MD",{"facility":372,"status":69,"city":373,"state":374,"zip":375,"country":73,"countryCode":74,"cosmosGeoPoint":376,"geoPoint":380,"contacts":381},"Austin Clinical Research","Austin","Texas","78750",{"type":76,"coordinates":377},[378,379],-97.74306,30.26715,{"lat":379,"lon":378},[382,385],{"name":383,"role":63,"phone":51,"phoneExt":51,"email":384},"Ivana Gunderson","igunderson@retinaresearchcenter.net",{"name":386,"role":87,"phone":51,"phoneExt":51,"email":51},"Fuad Makkouk, M.D.",{"facility":388,"status":69,"city":389,"state":374,"zip":390,"country":73,"countryCode":74,"cosmosGeoPoint":391,"geoPoint":395,"contacts":396},"Valley Retina Institute, PA","McAllen","78503",{"type":76,"coordinates":392},[393,394],-98.23001,26.20341,{"lat":394,"lon":393},[397,400],{"name":398,"role":63,"phone":51,"phoneExt":51,"email":399},"Yesenia Salinas","yesenia.salinas@eyeptcare.com",{"name":401,"role":87,"phone":51,"phoneExt":51,"email":51},"Victor Gonzalez, M.D.",{"facility":403,"status":298,"city":404,"state":374,"zip":405,"country":73,"countryCode":74,"cosmosGeoPoint":406,"geoPoint":410,"contacts":51},"Retina Consultants of Texas","The Woodlands","77384",{"type":76,"coordinates":407},[408,409],-95.48938,30.15799,{"lat":409,"lon":408},{"facility":412,"status":298,"city":413,"state":414,"zip":415,"country":73,"countryCode":74,"cosmosGeoPoint":416,"geoPoint":420,"contacts":51},"Pacific Northwest Retina LLC","Bellevue","Washington","98004",{"type":76,"coordinates":417},[418,419],-122.20068,47.61038,{"lat":419,"lon":418},{"facility":422,"status":69,"city":423,"state":424,"zip":425,"country":424,"countryCode":426,"cosmosGeoPoint":427,"geoPoint":431,"contacts":432},"Emanuelli Research and Development Center, LLC","Arecibo","Puerto Rico","00612","PR",{"type":76,"coordinates":428},[429,430],-66.71573,18.47245,{"lat":430,"lon":429},[433,436],{"name":434,"role":63,"phone":51,"phoneExt":51,"email":435},"Diane Perez","dperez@erdpr.com",{"name":437,"role":87,"phone":51,"phoneExt":51,"email":51},"Andres Emanuelli, MD",{"type":439,"investigatorFullName":51,"investigatorTitle":51,"investigatorAffiliation":51,"oldNameTitle":51,"oldOrganization":51},"SPONSOR","100454417","phase-1-4d-150-in-patients-with-neovascular-wet-age-related-macular-degeneration-100454417",false,"NCT05197270","4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration","A Phase 1\u002F2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults With Neovascular (Wet) Age-Related Macular Degeneration","* 50 years of age\n\nIndividuals eligible to participate in the trial must meet the following inclusion criteria:\n\n1. ≥50 years of age\n2. Diagnosed with CNV secondary to AMD (confirmed by reading center)\n3. BCVA ≥34 ETDRS letters (\\~20\u002F200) in the contralateral eye, and BCVA in the study eye:\n4. Central subfield thickness (CST) and\u002For presence of subretinal or intraretinal fluid requiring continued anti-VEGF therapy in the study eye, as assessed by SD-OCT; and confirmed by a reading center):\n5. Study eye amenable to IVT injection\n6. Ability to perform tests of visual and retinal function and structure, and ability to comply with other protocol-specified procedures\n7. Currently receiving anti-VEGF treatment (e.g. ranibizumab, aflibercept, faricimab or bevacizumab) in the study eye AND has demonstrated a clinical response consistent with anti-VEGF activity within 12 months prior to screening:\n\n   Note: Day -7 aflibercept will be administered ≥ 4 weeks from last IVT anti-VEGF\n8. Subjects receiving 4D-150 agree to use a barrier method (e.g. condom) during intercourse for 6 months after administration of 4D-150 to prevent fluid transmission; sexually active males should not father a child or donate sperm during this period\n9. Medical records available to document history of anti-VEGF therapy (dates, drugs, and dosage) for a minimum of 12 months prior to Screening\n10. Provide written informed consent.\n\nContralateral Eye Sub-study-Specific Criteria:\n\n1. Received 4D-150 in study eye-1 at least 6 months prior to Contralateral Substudy Screening Visit NOTE: Subjects who received 4D-150 in study eye-1 as part of the Shedding Substudy are also eligible to participate in the Contralateral Eye Substudy only after biological samples from all matrices were at or below the limit of quantitation for vector genomes in at least 3 consecutive measurements AND at least 6 months has passed since 4D-150 administration to study eye-1.\n2. Macular neovascularization (MNV) secondary to AMD in study eye-2 as assessed on historical images at any time by SD-OCT (required) and FA when available or fundus photography when available or at screening based on SD-OCT, FA and fundus photography (confirmed by the reading center)\n3. History of at least 1 anti-VEGF injection in study eye-2 within 6 months prior to Screening (last anti-VEGF injection must be at least 28 days prior to Screening) AND has demonstrated a clinical response consistent with anti-VEGF activity by historical OCT at any time point prior to screening with confirmed response by the reading center (Screening OCT can be confirmatory)\n4. BCVA between 25 and 83 ETDRS letters, inclusive (20\u002F320 20\u002F25 Snellen) in study eye-2\n5. Study eye-2 amenable to IVT injection\n6. BCVA ≥34 ETDRS letters (\\~20\u002F200) in the previously treated study eye-1\n7. Ability to comply with protocol-specified procedures and visits, in the Investigator's judgment\n8. Agree to use a barrier method (e.g. condom) during intercourse for 6 months after administration of 4D-150 to study eye-2 to prevent fluid transmission; sexually active males should not father a child or donate sperm during this period\n9. Provide written informed consent.\n\nShedding Substudy-specific Inclusion Criteria:\n\n1. ≥50 years of age\n2. Diagnosed with MNV secondary to AMD as assessed on historical images at any time by spectral domain optical coherence tomography (SD-OCT) (required) and fluorescein angiography when available or fundus photography when available or at screening based on SD-OCT, FA and fundus photography (confirmed by Reading Center)\n3. Best corrected visual acuity (BCVA) between 10 and 83 ETDRS letters, inclusive (\\~20\u002F640 and 20\u002F25, respectively) in the study eye at Screening\n4. BCVA ≥34 ETDRS letters (\\~20\u002F200) in the contralateral eye\n5. Currently receiving anti-VEGF treatment (e.g. ranibizumab, aflibercept, faricimab or bevacizumab) in the study eye; minimum of 1 injection within the last 6 months (last anti-VEGF injection must be at least 28 days prior to screening) AND has demonstrated a clinical response consistent with anti-VEGF activity by historical OCT at any time prior to screening with confirmed response by the reading center (Screening OCT can be confirmatory)\n6. Study eye amenable to IVT injection\n7. Ability to perform tests of visual and retinal function and structure, and ability to comply with other protocol-specified procedures, in the Investigator's judgment\n8. Agree to use a barrier method (e.g. condom) during intercourse for 6 months after administration of 4D-150 to prevent fluid transmission; sexually active males should not father a child or donate sperm during this period\n9. Provide written informed consent.","ALL","50 Years",{"count":450,"type":451},215,"ESTIMATED","INTERVENTIONAL",[454,455],"PHASE1","PHASE2","Phase 1\u002F2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment.\n\nSubstudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.",[458],"Neovascular (Wet) Age-Related Macular Degeneration",[460,461,462,463,464,465,466,467,468,469,470,471,472,473],"Age-related macular degeneration","AMD","Exudative AMD","Exudative age-related macular degeneration","Neovascular AMD","Neovascular age-related macular degeneration","Wet age-related macular degeneration","Wet macular degeneration","Wet AMD","wAMD","Retinal gene therapy","Intravitreal gene therapy","Genetic Medicine","Ocular Gene Therapy","2026-02-10",{"date":476,"type":477},"2026-02-12","ACTUAL",{"date":479,"type":477},"2021-12-09",{"date":481,"type":451},"2031-01",{"name":5,"class":6},25]